Global Drug Repurposing Market Analysis 2025–2029: Opportunities for Strategic Growth

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Larger Is The Drug Repurposing Market Expected To Become By 2029 Compared With Its 2025 Level?

The drug repurposing market size has experienced substantial growth in recent years. It is anticipated to expand from $34.12 billion in 2024 to $37.38 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 9.5%. This past growth is primarily due to the escalating cost of novel drug development, an increase in drug failures during clinical trials, a heightened demand for faster drug approval, the growing availability of off-patent drugs, and increased government and academic funding for research.

The market size for drug repurposing is projected to witness significant growth in the upcoming years. It is foreseen to expand to $53.42 billion by 2029, achieving a compound annual growth rate (CAGR) of 9.3%. This projected growth can be ascribed to a rising need for cost-effective therapies, increased financial commitments from pharmaceutical companies, a surge in collaborations among biotech firms, and the broadening of applications within oncology and neurology. Prominent trends throughout the forecast period encompass improvements in computational drug discovery instruments, advanced application of artificial intelligence and machine learning in drug repurposing, novel developments in predictive modeling for drug efficacy, the integration of big data analytics into drug screening, and breakthroughs in biomarker identification.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25758&type=smp

What Are The Top Growth Drivers Impacting The Drug Repurposing Market Outlook?

The increasing occurrence of neurodegenerative diseases is projected to propel the expansion of the drug repurposing market moving forward. These conditions refer to a group of disorders characterized by the gradual deterioration or loss of neuronal structure or function, including their death. The rise in neurodegenerative diseases, such as alzheimer’s dementia, is linked to increased life expectancy, given that aging is the primary risk factor contributing to the progressive decline of neuronal function over time. Drug repurposing aids in combating neurodegenerative diseases by identifying existing medications with known safety profiles that can be redirected to target disease pathways, thereby accelerating the development of effective treatments. For instance, in March 2023, according to the Alzheimer’s Association, a US-based nonprofit voluntary health organization, in 2023, approximately 6.7 million Americans aged 65 and older are living with Alzheimer’s dementia, with projections indicating an increase to 13.8 million by 2060. Consequently, the growing prevalence of neurodegenerative diseases is driving the growth of the drug repurposing market.

What Are The Segment Types Shaping The Drug Repurposing Market?

The drug repurposing market covered in this report is segmented –

1) By Type: Disease-Centric, Target-Centric, Drug-Centric

2) By Drug Molecules: Biologics, Small Molecule

3) By Therapeutic Area: Oncology, Neurology, Infectious Diseases, Cardiovascular Diseases, Autoimmune Disorders

4) By Route Of Administration: Oral, Intravenous, Topical, Inhalation, Intramuscular

5) By End-User: Pharmaceutical Companies, Research And Academic Institutes, Contract Research Organizations

Subsegments:

1) By Disease-Centric: Phenotypic Screening, Epidemiological Analysis, Clinical Observation-Based Repurposing

2) By Target-Centric: Protein Target Modulation, Pathway Modulation, Biomarker-Based Targeting

3) By Drug-Centric: Off-Target Activity Identification, Structure-Based Drug Repositioning, Adverse Effect-Based Repurposing

Which Competitive Trends Are Defining The Drug Repurposing Market Structure?

Leading companies within the drug repurposing sector are concentrating their efforts on creating sophisticated technologies, like artificial intelligence (AI)-driven drug-protein interaction modeling, aiming to expedite the discovery of novel therapeutic applications for existing medicines. This AI-driven drug-protein interaction modeling utilizes artificial intelligence and machine learning techniques to forecast drug-protein interactions throughout the human proteome, employing extensive datasets to bolster precision and reliability. As an illustration, in July 2025, Cosmos Health Inc., a US-based healthcare firm, launched Cloudscreen 2.0, which is an advanced artificial intelligence platform specifically for drug repurposing. This next-generation system is engineered to handle datasets exceeding 100 times their previous size, facilitating a thorough analysis of drug-protein interactions. Through the integration of mutagenesis data and instruments for examining disordered proteins, the platform addresses conditions like cancer, obesity, and diabetes. Furthermore, graphics processing unit (GPU)-based cloud computing provides scalable processing capabilities, establishing the platform as a vital advancement in speeding up research and development trajectories for drug repurposing across various therapeutic domains.

Who Are The Major Companies Operating In The Drug Repurposing Market?

Major companies operating in the drug repurposing market are F. Hoffmann-La Roche Ltd , International Business Machines Corporation (IBM), Bayer AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., UCB S.A., Eisai Co Ltd., Celltrion Inc., Alnylam Pharmaceuticals Inc., Evotec SE, BenevolentAI Limited, Insilico Medicine Inc., Cosmos Health Inc., Recursion Pharmaceuticals Inc., Pharnext S.A., Healx Ltd., Algernon Pharmaceuticals Inc., BioXcel Therapeutics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/drug-repurposing-global-market-report

How Do Regional Market Performances Compare Within The Drug Repurposing Industry?

North America was the largest region in the drug repurposing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug repurposing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Drug Repurposing Market Report:

https://www.thebusinessresearchcompany.com/customise?id=25758&type=smp

Browse Through More Reports Similar to the Global Drug Repurposing Market 2025, By The Business Research Company

Pharmacy Repackaging Systems Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pharmacy-repackaging-systems-global-market-report

Music Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/music-therapy-global-market-report

Personal Development Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/personal-development-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795